Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ALLO-715 / Allogene Therap
UNIVERSAL, NCT04093596: Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma Data from UNIVERSAL trial for r/r multiple myeloma Jan 2023 - Jan 2023: Data from UNIVERSAL trial for r/r multiple myeloma Dose escalation data from UNIVERSAL trial in heavily pretreated r/r multiple myeloma Nov 2022 - Nov 2022: Dose escalation data from UNIVERSAL trial in heavily pretreated r/r multiple myeloma Safety and tolerability data from UNIVERSAL trial for multiple myeloma Nov 2022 - Nov 2022: Safety and tolerability data from UNIVERSAL trial for multiple myeloma Data from UNIVERSAL trial in combination with nirogacestat for r/r multiple myeloma at ASH 2021 Dec 2021 - Dec 2021: Data from UNIVERSAL trial in combination with nirogacestat for r/r multiple myeloma at ASH 2021 Initial data from UNIVERSAL trial in combination with nirogacestat for r/r multiple myeloma at ASCO 2021 Apr 2021 - Apr 2021: Initial data from UNIVERSAL trial in combination with nirogacestat for r/r multiple myeloma at ASCO 2021 Initiated dosing for UNIVERSAL study in combination with nirogacestat for r/r multiple myeloma Apr 2021 - Apr 2021: Initiated dosing for UNIVERSAL study in combination with nirogacestat for r/r multiple myeloma Data from UNIVERSAL trial for r/r multiple myeloma at ASH 2020 Dec 2020 - Dec 2020: Data from UNIVERSAL trial for r/r multiple myeloma at ASH 2020 More	Active, not recruiting	1	132	US	ALLO-715, ALLO-647, Fludarabine, Cyclophosphamide, Nirogacestat	Allogene Therapeutics	Relapsed/Refractory Multiple Myeloma	09/27	09/27